Improvement of Chronic Hepatitis B by Iron Chelation Therapy in a Patient with Iron Overload: A Case Report

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Feb 1

PMID 29384977

Citations 2

Authors

Dong-Mei Zou

Dong-Dong Rong

Hong Zhao

Li Su

Wan-Ling Sun

Affiliations

Soon will be listed here.

Abstract

Rationale: This report describes seroconversion of hepatitis B surface antigen (HBsAg) in a patient with marked iron overload caused by chronic hepatitis B (CHB) after receiving iron chelation therapy and discusses the role of iron chelation therapy in CHB.

Patient Concerns: Increased serum ferritin level for 2 months.

Diagnosis: Secondary iron overload and CHB.

Intervention: To relieve iron load of the body, the patient underwent regular phlebotomy therapy and deferoxamine (DFO) therapy. During the therapy, serum ferritin and hepatitis B virus (HBV) were monitored and the iron concentration of the liver and heart were followed by T2* of magnetic resonance imaging (MRI) scan.

Outcomes: Serum ferritin gradually decreased. Approximately 1 year after the therapy, HBsAg turned persistently negative.

Lessons: Iron chelation therapy may attenuate HBV infection.

Citing Articles

Therapeutic Potential of Iron Chelators in Viral Diseases: A Systematic Review.

Lori M, Khandani A, Dehghannoudeh G, Ohadi M, Ansari M Curr Med Chem. 2024; 31(27):4383-4391.

PMID: 38321902 DOI: 10.2174/0109298673259596231211113211.

Secondary Iron Overload and the Liver: A Comprehensive Review.

Pinyopornpanish K, Tantiworawit A, Leerapun A, Soontornpun A, Thongsawat S J Clin Transl Hepatol. 2023; 11(4):932-941.

PMID: 37408825 PMC: 10318281. DOI: 10.14218/JCTH.2022.00420.

References

Bacon B, Adams P, Kowdley K, Powell L, Tavill A . Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(1):328-43. PMC: 3149125. DOI: 10.1002/hep.24330. View

Sebastiani G, Walker A . HFE gene in primary and secondary hepatic iron overload. World J Gastroenterol. 2007; 13(35):4673-89. PMC: 4611189. DOI: 10.3748/wjg.v13.i35.4673. View

Castoldi M, Vujic Spasic M, Altamura S, Elmen J, Lindow M, Kiss J . The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest. 2011; 121(4):1386-96. PMC: 3069782. DOI: 10.1172/JCI44883. View

Di Bisceglie A, Axiotis C, Hoofnagle J, Bacon B . Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992; 102(6):2108-13. DOI: 10.1016/0016-5085(92)90339-z. View

Wang X, Cheng P, Jiang F, Jiao X . The effect of hepatitis B virus infection on hepcidin expression in hepatitis B patients. Ann Clin Lab Sci. 2013; 43(2):126-34. View

Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H . Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol. 2000; 95(4):1041-50. DOI: 10.1111/j.1572-0241.2000.01979.x. View

Pra D, Franke S, Henriques J, Fenech M . Iron and genome stability: an update. Mutat Res. 2012; 733(1-2):92-9. DOI: 10.1016/j.mrfmmm.2012.02.001. View

PROPST A, Graziadei I, Herold M, Propst T, Vogel W . The acute phase protein alpha-1-antitrypsin inhibits transferrin uptake in PLC/PRF/5 cells and increases release of hepatitis B virus surface antigen and alpha-fetoprotein. Eur J Gastroenterol Hepatol. 1998; 10(6):497-502. DOI: 10.1097/00042737-199806000-00011. View

. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010; 53(1):3-22. DOI: 10.1016/j.jhep.2010.03.001. View

10.

Chen X, Zhang H, Yang Q, Luo Z, Zhang Z, Cheng Z . Value of severe liver iron overload for assessing heart iron levels in thalassemia major patients. J Magn Reson Imaging. 2016; 44(4):880-9. DOI: 10.1002/jmri.25238. View

11.

Fang C, Zhao C, Liu X, Yang P, Lu H . Protein alteration of HepG2.2.15 cells induced by iron overload. Proteomics. 2012; 12(9):1378-90. DOI: 10.1002/pmic.201100335. View

12.

Park S, Kumar M, Gupta S . TGF-β and iron differently alter HBV replication in human hepatocytes through TGF-β/BMP signaling and cellular microRNA expression. PLoS One. 2012; 7(6):e39276. PMC: 3377643. DOI: 10.1371/journal.pone.0039276. View

13.

Blumberg B, Lustbader E, Whitford P . Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci U S A. 1981; 78(5):3222-4. PMC: 319533. DOI: 10.1073/pnas.78.5.3222. View

14.

Noetzli L, Carson S, Nord A, Coates T, Wood J . Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008; 112(7):2973-8. PMC: 2556627. DOI: 10.1182/blood-2008-04-148767. View

15.

Lavanchy D . Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2):97-107. DOI: 10.1046/j.1365-2893.2003.00487.x. View

16.

Marcellin P, Heathcote E, Buti M, Gane E, de Man R, Krastev Z . Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23):2442-55. DOI: 10.1056/NEJMoa0802878. View

17.

Lustbader E, Hann H, Blumberg B . Serum ferritin as a predictor of host response to hepatitis B virus infection. Science. 1983; 220(4595):423-5. DOI: 10.1126/science.6301008. View

18.

Van Thiel D, Friedlander L, Fagiuoli S, Wright H, Irish W, Gavaler J . Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994; 20(3):410-5. DOI: 10.1016/s0168-8278(94)80017-0. View

19.

Sutnick A, Blumberg B, Lustbader E . Letter: Elevated serum iron levels and persistent Australia antigen (HBsAG). Ann Intern Med. 1974; 81(6):855-6. DOI: 10.7326/0003-4819-81-6-855. View

20.

Ricchi P, Cinque P, Lanza Galeota A, Matola T, Ammirabile M, Prossomariti L . Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. Int J Hematol. 2008; 89(2):135-138. DOI: 10.1007/s12185-008-0229-6. View